Annals of Coloproctology

Display

Sort by :

Original Articles

ERCC1 as a Predictive Marker for FOLFOX Chemotherapy in an Adjuvant Setting: Chee Young Kim, Sang Hyuk Seo, Min Sung An, Kwang Hee Kim, Ki Beom Bae, Jin Won Hwang, Ji Hyun Kim, Bo Mi Kim, Mi Seon Kang, Min Kyung Oh, Kwan Hee Hong; Ann Coloproctol. 2015;31(3):92-97. Published online June 30, 2015; DOI: https://doi.org/10.3393/ac.2015.31.3.92

5,664 View
43 Download
7 Web of Science
6 Citations

Purpose

The purpose of this study was to identify the excision repair cross-complementation group 1 (ERCC1) as a predictive marker for FOLFOX adjuvant chemotherapy in stages II and III colon cancer patients.

Methods

A total of 166 high risk stages II and III colon cancer patients were retrospectively enrolled in this study, and data were collected prospectively. They underwent a curative resection followed by FOLFOX4 adjuvant chemotherapy. We analyzed ERCC1 expression in the primary colon tumor by using immunohistochemical staining. The oncological outcomes included the 5-year disease-free survival (DFS) rate. The DFS was analyzed by using the Kaplan-Meier method with the log-rank test. A Cox proportional hazard model was used for the prognostic analysis.

Results

ERCC1-positive expression was statistically significant in the older patients (P = 0.032). In the multivariate analysis, the prognostic factors for DFS were female sex (P = 0.016), N stage (P = 0.009), and postoperative carcinoembryonic antigen level (P = 0.001), but ERCC1 expression was not a statistically significant prognostic factor for DFS in the univariate analysis (P = 0.397). The 5-year DFS rate was not significantly associated with the ERCC1 expression in all patients (P = 0.396) or with stage III disease (P = 0.582).

Conclusion

We found that ERCC1 expression was not significantly correlated with the 5-year DFS as reflected by the oncologic outcomes in patients with high-risk stages II and III colon cancer treated with FOLFOX adjuvant chemotherapy.

Citations

Citations to this article as recorded by

ERCC1 and MGMT Methylation as a Predictive Marker of Relapse and FOLFOX Response in Colorectal Cancer Patients from South Tunisia
Dhouha Jamai, Raja Gargouri, Boulbaba Selmi, Abdelmajid Khabir
Genes.2023; 14(7): 1467. CrossRef
EXPRESSION OF NUCLEOTIDE EXCISION REPAIR PROTEIN ERCC1 IN TUMOR TISSUE AS A PROGNOSTIC FACTOR IN COLORECTAL CANCER
Irina Aleksandrovna Bogomolova, Dinara Rishatovna Dolgova, Inna Ivanovna Antoneeva, Ekaterina Gennad'evna Parmenova, Il'seya Rinatovna Myagdieva, Mark Alekseevich Urevskiy
Ulyanovsk Medico-biological Journal.2023; (3): 167. CrossRef
ERCC1, PARP-1, and AQP1 as predictive biomarkers in colon cancer patients receiving adjuvant chemotherapy
Aziza E. Abdelrahman, Doaa Abdelaziz Ibrahim, Ahmed El-Azony, Ahmed A. Alnagar, Amr Ibrahim
Cancer Biomarkers.2020; 27(2): 251. CrossRef
Using patient-derived xenograft models of colorectal liver metastases to predict chemosensitivity
Kai M. Brown, Aiqun Xue, Sohel M. Julovi, Anthony J. Gill, Nick Pavlakis, Jaswinder S. Samra, Ross C. Smith, Thomas J. Hugh
Journal of Surgical Research.2018; 227: 158. CrossRef
Predictive Biomarkers in Colorectal Cancer: From the Single Therapeutic Target to a Plethora of Options
Daniela Rodrigues, Adhemar Longatto-Filho, Sandra F. Martins
BioMed Research International.2016; 2016: 1. CrossRef
ERCC1 and the Prognosis for Patients With Colon Cancer Receiving Oxaliplatin-Based Adjuvant Chemotherapy
Moo-Jun Baek
Annals of Coloproctology.2015; 31(3): 81. CrossRef

Association Between a Close Distal Resection Margin and Recurrence After a Sphincter-Saving Resection for T3 Mid- or Low-Rectal Cancer Without Radiotherapy: Jae Woong Han, Min Jae Lee, Ha Kyung Park, Jae Ho Shin, Min Sung An, Tae Kwun Ha, Kwang Hee Kim, Ki Beom Bae, Tae Hyun Kim, Chang Soo Choi, Sang Hoon Oh, Min Kyung Oh, Mi Seon Kang, Kwan Hee Hong; Ann Coloproctol. 2013;29(6):231-237. Published online December 31, 2013; DOI: https://doi.org/10.3393/ac.2013.29.6.231

5,553 View
23 Download
7 Citations

Abstract PDF

Purpose

To maintain the patient's quality of life, surgeons strive to preserve the sphincter during rectal cancer surgery. This study evaluated the oncologic safety of a sphincter-saving resection with a distal resection margin (DRM) <1 cm without radiotherapy in T3, mid- or low-rectal cancer.

Methods

This retrospective study enrolled 327 patients who underwent a sphincter-saving resection for proven T3 rectal cancer located <10 cm from the anal verge and without radiotherapy between January 1995 and December 2011. The oncologic outcomes included the 5-year cancer-specific survival, the local recurrence, and the systemic recurrence rates.

Results

In groups A (DRM ≤1 cm) and B (DRM >1 cm), the 5-year cancer-specific survival rates were 81.57% and 80.03% (P = 0.8543), the 5-year local recurrence rates were 6.69% and 9.52% (P = 0.3981), and the 5-year systemic recurrence rates were 19.46% and 23.11% (P = 0.5750), respectively.

Conclusion

This study showed that the close DRM itself should not be a contraindication for a sphincter-saving resection for T3 mid- or low-rectal cancer without radiotherapy. However, a prospective randomized controlled trial including the effect of adjuvant therapy will be needed.

Citations

Citations to this article as recorded by

The Impact of Narrow and Infiltrated Distal Margin After Proctectomy for Rectal Cancer on Patients’ Outcomes: a Systematic Review and Meta-analysis
Islam H. Metwally, Mohammad Zuhdy, Omar Hamdy, Ahmed M. Fareed, Saleh S. Elbalka
Indian Journal of Surgical Oncology.2022; 13(4): 750. CrossRef
Association of levels of metabolites with the safe margin of rectal cancer surgery: a metabolomics study
Shaopeng Zhang, Guoqiang Pan, Zhifeng Liu, Yuan Kong, Daguang Wang
BMC Cancer.2022;[Epub] CrossRef
Distal resection margins in rectal cancer specimens: differences in assessment between surgeons and pathologists and the influence of neoadjuvant chemoradiation
T. L. Ghezzi, C. Tarta, P. C. Contu, A. R. Lazzaron, B. M. Contin, L. M. Kliemann, D. C. Damin
Updates in Surgery.2021; 73(5): 1787. CrossRef
Surgical margins in squamous cell carcinoma, different for the vulva?
Noortje Pleunis, Maria E.J. Leermakers, Anneke A. van der Wurff, Paul J.J.M. Klinkhamer, Nicole P.M. Ezendam, Dorry Boll, Joanne A. de Hullu, Johanna M.A. Pijnenborg
European Journal of Surgical Oncology.2018; 44(10): 1555. CrossRef
Continuous Effect of Radial Resection Margin on Recurrence and Survival in Rectal Cancer Patients Who Receive Preoperative Chemoradiation and Curative Surgery: A Multicenter Retrospective Analysis
SooYoon Sung, Sung Hwan Kim, Joo Hwan Lee, Taek Keun Nam, Songmi Jeong, Hong Seok Jang, Jin Ho Song, Jeong Won Lee, Jung Min Bae, Jong Hoon Lee
International Journal of Radiation Oncology*Biology*Physics.2017; 98(3): 647. CrossRef
Efficacy and Safety of Low-Dose-Rate Endorectal Brachytherapy as a Boost to Neoadjuvant Chemoradiation in the Treatment of Locally Advanced Distal Rectal Cancer: A Phase-II Clinical Trial
Shapour Omidvari, Shadi Zohourinia, Mansour Ansari, Leila Ghahramani, Mohammad Zare-Bandamiri, Ahmad Mosalaei, Niloofar Ahmadloo, Saeedeh Pourahmad, Hamid Nasrolahi, Sayed Hasan Hamedi, Mohammad Mohammadianpanah
Annals of Coloproctology.2015; 31(4): 123. CrossRef
Safe Distal Resection Margin in Patients With T3 Mid and Distal Rectal Cancer Who Underwent a Sphincter-Saving Resection Without Preoperative Radiotherapy
Bong Hwa Lee, Hyoung Chul Park, Min Jeong Kin, Mi Young Jang
Annals of Coloproctology.2013; 29(6): 219. CrossRef

First
Prev
Page of 1
Next
Last

Search